Related references
Note: Only part of the references are listed.Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults
Caroline Ogwang et al.
PLOS ONE (2013)
The Relationship between RTS,S Vaccine-Induced Antibodies, CD4+ T Cell Responses and Protection against Plasmodium falciparum Infection
Michael T. White et al.
PLOS ONE (2013)
Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector
Geraldine A. O'Hara et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
ChAd63-MVA-vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans
Susanne H. Sheehy et al.
MOLECULAR THERAPY (2012)
A review of malaria vaccine clinical projects based on the WHO rainbow table
Lauren Schwartz et al.
MALARIA JOURNAL (2012)
Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors
Susanne H. Sheehy et al.
PLOS ONE (2012)
Viral vectors as vaccine platforms: deployment in sight
Christine S. Rollier et al.
CURRENT OPINION IN IMMUNOLOGY (2011)
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial
Ally Olotu et al.
LANCET INFECTIOUS DISEASES (2011)
Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors
Susanne H. Sheehy et al.
MOLECULAR THERAPY (2011)
Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria
Ally Olotu et al.
PLOS ONE (2011)
Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults
Martha Sedegah et al.
PLOS ONE (2011)
Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component
Cindy Tamminga et al.
PLOS ONE (2011)
Vaccines against malaria
Adrian V. S. Hill
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2011)
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects
Michael C. Keefer et al.
VACCINE (2011)
Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates
Stefania Capone et al.
VACCINE (2010)
Genetically Attenuated Parasite Vaccines Induce Contact-Dependent CD8+ T Cell Killing of Plasmodium yoelii Liver Stage-Infected Hepatocytes
Adama Trimnell et al.
JOURNAL OF IMMUNOLOGY (2009)
Randomized, Double-Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria-Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
Kent E. Kester et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan Children, in the context of vaccine vector efficacy
M. Dudareva et al.
VACCINE (2009)
Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research
Kent E. Kester et al.
VACCINE (2008)
Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite
Agam Prasad Singh et al.
CELL (2007)
Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells
Alice S. Tarun et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex class I-dependent interferon-γ-producing CD8+ T cells
Ousman Jobe et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells
Ann-Kristin Mueller et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
A CD46-binding chimpanzee adenovirus vector as a vaccine carrier
Nia Tatsis et al.
MOLECULAR THERAPY (2007)
Safety and immunogenicity of the malaria candidate vaccines FP9CS and MVA CS in adult Gambian men
E. B. Imoukhuede et al.
VACCINE (2006)
A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya
Philip Bejon et al.
PLOS CLINICAL TRIALS (2006)
A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge
S. J. Dunachie et al.
INFECTION AND IMMUNITY (2006)
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein
M Walther et al.
INFECTION AND IMMUNITY (2006)
Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya
P Bejon et al.
CLINICAL INFECTIOUS DISEASES (2006)
A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS
SJ Dunachie et al.
VACCINE (2006)
Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers
DP Webster et al.
VACCINE (2006)
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
DP Webster et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion
A Coppi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif
O Bruna-Romero et al.
VACCINE (2004)
Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in gambian men
VS Moorthy et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults
VS Moorthy et al.
PLOS MEDICINE (2004)
Protracted protection to Plasmodium berghei malaria is linked to functionally and phenotypically heterogeneous liver memory CD8+ T cells
D Berenzon et al.
JOURNAL OF IMMUNOLOGY (2003)
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
SJ McConkey et al.
NATURE MEDICINE (2003)
Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites
SL Hoffman et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays
JR Currier et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2002)
The complexity of protective immunity against liver-stage malaria
DL Doolan et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
